Prosecution Insights
Last updated: April 19, 2026
Application No. 17/797,666

IL-10 AND USES THEREOF

Non-Final OA §102
Filed
Aug 04, 2022
Examiner
STOICA, ELLY GERALD
Art Unit
1647
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bristol-Myers Squibb Company
OA Round
1 (Non-Final)
67%
Grant Probability
Favorable
1-2
OA Rounds
2y 8m
To Grant
89%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allow Rate
807 granted / 1211 resolved
+6.6% vs TC avg
Strong +23% interview lift
Without
With
+22.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
31 currently pending
Career history
1242
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
26.7%
-13.3% vs TC avg
§102
19.9%
-20.1% vs TC avg
§112
34.1%
-5.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1211 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I (claims 1, 7, 9, 15-17, 19 and 50) in the reply filed on 10/16/2025 is acknowledged. Claims 1, 7, 9, 15-17, 19, 34, 39, 44-45, 50-54, 59, 60, 72, and 77 are pending; claims 34, 39, 44-45, 51-54, 59, 60, 72, and 77 are withdrawn from prosecution as being drawn to non-elected subject matter. Claims 1, 7, 9, 15-17, 19 and 50 are examined. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 7, 9, 15-17, 19 and 50 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Duerner et al. (U.S. Pat. No. 9, 346, 872). The reference generally relates to fusion proteins of antibodies and interleukin-10 (IL-10), to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides (Abstract). SEQ ID NO: 9 of the reference is 98.2% identical to the SEQ ID NO:14 of the instant Application. In addition, the reference indicated pharmaceutical compositions comprising SEQ ID NO: 9 (col. 6, lines 42-62). Thus, in the broadest reasonable interpretation, the claims are anticipated by the reference cited. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ELLY GERALD STOICA whose telephone number is (571)272-9941. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joanne Hama can be reached at 571-272-2911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ELLY-GERALD STOICA Primary Examiner Art Unit 1647 /Elly-Gerald Stoica/Primary Examiner, Art Unit 1647
Read full office action

Prosecution Timeline

Aug 04, 2022
Application Filed
Oct 30, 2025
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600785
Method of screening for compounds that inhibit proliferation of pancreatic cancer cells having a loss -of-function mutation in the RNF43 gene
2y 5m to grant Granted Apr 14, 2026
Patent 12600773
Treatment of diuretic resistant heart failure patients having at least one copy of the TMPRSS6 rs855791 allele
2y 5m to grant Granted Apr 14, 2026
Patent 12590145
TRANSFORMING GROWTH FACTOR-BETA-RESPONSIVE POLYPEPTIDES AND THEIR METHODS FOR USE
2y 5m to grant Granted Mar 31, 2026
Patent 12583928
NOVEL IGFR-LIKE RECEPTOR AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12582675
METHODS FOR TREATMENT OF CANCERS HARBORING AN H3K27M MUTATION
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
67%
Grant Probability
89%
With Interview (+22.7%)
2y 8m
Median Time to Grant
Low
PTA Risk
Based on 1211 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month